Piramal Pharma informs about disclosure

02 Jun 2025 Evaluate

Piramal Pharma has informed that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of the company’s facility at Aurora, Canada from 26th May 2025 to 30th May, 2025. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation. The Company remains committed to maintain the highest standards of compliance.

The above information is a part of company’s filings submitted to BSE.

Piramal Pharma Share Price

178.50 8.60 (5.06%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×